Search Results

Terumo Cardiovascular, a global leader in cardiovascular surgery technologies, announced that the U.S. Food and Drug Administration has granted 510 clearance for the CDI OneView Monitoring System.

Terumo Medical Corporation is pleased to announce the launch of its new AZUR HydroPack Peripheral Coil System in the United States.

NAMSA, a world-leading MedTech Contract Research Organization offering global end-to-end development services, and Terumo Aortic, a developer of aorta-focused medical devices, announced that they have entered into a strategic outsourcing partnership to assist with the acceleration and commercialization of Terumo Aortic’s innovative aortic disease products.

Terumo Blood and Cell Technologies (Terumo BCT) announces U.S. Food and Drug Administration (FDA) clearance of the Reveos Automated Whole Blood Processing System, the first whole blood automation device available in the U.S. that processes whole blood into platelets and other components in a single centrifugation cycle.

Terumo Blood and Cell Technologies announces U.S. FDA clearance and official launch of its IMUGARD® WB Platelet Pooling Set, which supports extended shelf life of whole blood-derived platelets from five days to seven days..

Terumo Blood and Cell Technologies, a medical technology company, recently received U.S. Food and Drug Administration 510 clearance for the Rika Plasma Donation System™ with the iNomi™ Nomogram.

Terumo Cardiovascular, a global leader in medical devices for cardiac and vascular surgery, marked the opening of its newest manufacturing plant in La Lima, Cartago, Costa Rica.

Terumo Health Outcomes, a division of Terumo Medical Corporation, a leading global medical device manufacturer, has signed a collaboration and co-marketing agreement with Corazon, Inc., a leader in providing consulting, recruitment, interim management and accreditation services for heart, vascular, neuroscience and orthopedic specialty programs.

Terumo Corporation announced that it has established a global “DE&I Philosophy” to further cultivate the culture of Diversity, Equity, and Inclusion at the Terumo Group.

Terumo Blood and Cell Technologies (Terumo), a medical technology company, and Eliaz Therapeutics Inc. (ETI), a medical device company, today announced an exclusive collaboration to help combat AKI and S-AKI by focusing on the selective removal of an upstream inflammatory protein called Galectin-3 (Gal-3) from blood plasma.